Skip to main content
OpenTrials
Completed

NCT Number: NCT06883695

A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-3045 in healthy subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rheumatoid Arthritis Arthritis Arthritis, Rheumatoid Autoimmune Diseases Connective Tissue Diseases Immune System Diseases Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Shanghai General Hospital

Shanghai, Shanghai Municipality, 200080, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with ability to understand the trial procedures and possible adverse events, voluntary participation in the trial.
  • Subjects who can provide written informed consent.
  • Males or females aged 18-55 years (both inclusive).
  • Males with body weight ≥ 50 kg, or females with body weight ≥ 45 kg.
  • No clinically significant abnormalities in the medical history, general physical examinations, vital signs and laboratory tests.

Exclusion criteria

  • Participation in clinical trials of other investigational drugs or medical devices within 3 months prior to screening.
  • Known or suspected history of drug abuse.
  • Addiction to tobacco and alcohol.
  • Individuals who are unable to adhere to the dietary requirements of this trial during the study period.
  • Judged by the investigator, there are any other conditions that interfere with the results evaluation of the trial.

Treatment and study plan

SHR-3045 Injection

Drug

SHR-3045 injection.

SHR-3045 Placebo Injection

Drug

SHR-3045 placebo injection.

Primary outcomes

  1. Adverse events (AEs)

    Time frame: From screening period up to day 113.

Secondary outcomes

  1. Area under the concentration-time curve from time 0 to the last time point after SHR-3045 administration (AUC0-last).

    Time frame: Post-dose at day 1 to day 113.

  2. Area under the concentration-time curve from time 0 to infinity after SHR-3045 administration (AUC0-inf).

    Time frame: Post-dose at day 1 to day 113.

  3. Maximum observed concentration of SHR-3045 (Cmax).

    Time frame: Post-dose at day 1 to day 113.

  4. Time to maximum observed concentration of SHR-3045 (Tmax).

    Time frame: Post-dose at day 1 to day 113.

  5. Clearance of SHR-3045 (CL).

    Time frame: Post-dose at day 1 to day 113.

  6. Terminal elimination half-life of SHR-3045 (t1/2).

    Time frame: Post-dose at day 1 to day 113.

Sponsors and collaborators

Lead sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Industry

Registry information

Official study title

A Phase Ⅰ, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Mar 19, 2025
Registry last updated
Jun 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.